NCT03135808 (WISE) is a clinical trial in Sigmoid, Sigmoid Colon, Neoplasm, Cancer, sponsored by Royal Marsden NHS Foundation Trust.

Who is sponsoring NCT03135808?

NCT03135808 is sponsored by Royal Marsden NHS Foundation Trust.

What condition does NCT03135808 study?

NCT03135808 studies Sigmoid, Sigmoid Colon, Neoplasm, Cancer.

Is NCT03135808 still recruiting?

NCT03135808 is currently completed. Last updated 14 September 2018.

Last reviewed 2018-09-14 · How we verify

NCT03135808: WISE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Surgical Anatomy and 'Waisting' of the sIgmoid SpEcimen

Completed Last updated 14 September 2018

What this trial tests

trial in Sigmoid, Sigmoid Colon, Neoplasm, Cancer in 20 participants. Completed in 13 June 2018.

Timeline

18 May 2017

Primary endpoint
13 June 2018

13 June 2018

Quick facts

Lead sponsor	Royal Marsden NHS Foundation Trust
Status	Completed
Study type	OBSERVATIONAL
Enrollment	20
Start date	18 May 2017
Primary completion	13 June 2018
Estimated completion	13 June 2018
Sites	1 location across United Kingdom

Conditions studied

Sigmoid, Sigmoid Colon, Neoplasm, Cancer — all drugs for Sigmoid, Sigmoid Colon, Neoplasm, Cancer →

Sponsor

Royal Marsden NHS Foundation Trust

Who can join

18 and older, any sex, with Sigmoid, Sigmoid Colon, Neoplasm, Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Treatment of rectal cancer has improved to the extent that its local recurrence rates are now much lower than other sites in the large bowel. It has been found that higher rates of recurrence in the sigmoid section of the colon, just before the rectum. This might be due to a narrowing in the bowel, and difficulties identifying whether cancers are in the sigmoid or rectum. The aim is to investigate the bowel from 20 patients undergoing surgery for left sided colorectal cancer at the Royal Marsden. These patients would have routine investigations and treatments, but once the bowel has been removed, it would undergo a MRI scan and additional slices and photography during pathological analysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Royal Marsden NHS Foundation Trust trials

Trials by the same sponsor.

NCT07407686 — Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services · not yet recruiting
NCT07243834 — Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise · NA · recruiting
NCT06605833 — CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma · enrolling by invitation
NCT07008742 — Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Canc · recruiting
NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03135808 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Royal Marsden NHS Foundation Trust
Last refreshed: 14 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03135808.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing